abstract |
REFERS TO A CRYSTALLINE MONO-SULPHATE FORM OF 2-CHLORINE-4- [1- (4-FLUOR-PHENYL) -2,5-DIMETHYL-1H-IMIDAZOLE-4-ILETINYL] -PYRIDINE CHARACTERIZED BY AT LEAST 3 PEAKS CHOSEN AMONG THE FOLLOWING X-RAY DIFFRACTION PEAKS OBTAINED WITH A CUkALFA AT 2THETA DEGREES: 9.8: 13.4; 14.2; 18.1; 18.9; 22.6; 22.9; 25.7; 27.1 AND 29.9 (+ -0.2 2-THETA) AND AN INFRARED SPECTRUM THAT HAS BANDS ACCUSED AT 3068, 2730, 2618, 2236, 2213, 1628, 1587, 1569, 1518, 1384, 1374, 902, 855, 786 674 CM-1 (+ -3cm-1). ALSO REFERRED TO A PHARMACEUTICAL COMPOSITION AND A PREPARATION PROCEDURE WHICH CONSISTS OF THE FORMATION OF SALT WITH SULFURIC ACID IN 2-PROPANOL AND POSTERIOR SPONTANEOUS PRECIPITATION. SAID POLYMORPH IS ANTAGONIST OF THE mGLUR5 RECEPTOR USEFUL IN THE TREATMENT OF NEUROLIOGICAL DISORDERS SUCH AS ANXIETY, CHRONIC PAIN, PROTECTION AGAINST HEPATIC INJURY, URINARY INCONTINENCE, AMONG OTHERS |